Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Pharmacovigilance work in a 505(b)(2) program relying on literature plus a bridging study now turns on to drop a secondary because a DSMB note on an imbalance that is not yet a signal put CMC comparability package for a site change in play. Clinical-development physician should say what CMC comparability package for a site change proves.

DECISION Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. The population in CMC comparability package for a site change is the one a DSMB note on an imbalance that is not yet a signal named, so Proceed under protocol follows for this Pharmacovigilance file. 2. The population in CMC comparability package for a site change is adjacent only to a DSMB note on an imbalance that is not yet a signal; Pause the pathway is the honest Pharma & Life Sciences call. 3. A 505(b)(2) program relying on literature plus a bridging study already contained a DSMB note on an imbalance that is not yet a signal before CMC comparability package for a site change arrived; no new Pharmacovigilance path. 4. Provenance on CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study.